Ingrezza (valbenazine) Letter of Medical Necessity
Ingrezza (valbenazine) is the first FDA-approved treatment for tardive dyskinesia and is frequently subject to step-therapy or prior-auth requirements favoring Austedo. An effective Letter of Medical Necessity documents TD diagnosis with AIMS scoring, dopamine antagonist exposure history, and clinical rationale for once-daily valbenazine.
FDA-Approved Indications
- ● tardive dyskinesia (TD) in adults
- ● chorea associated with Huntington's disease
Why Ingrezza Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Tardive dyskinesia diagnosis not documented (requires exposure to dopamine receptor blocking agents)
- 2. AIMS (Abnormal Involuntary Movement Scale) score not on file
- 3. History of dopamine receptor blocking agent exposure not documented (antipsychotic, metoclopramide, etc.)
- 4. Austedo (deutetrabenazine) as preferred VMAT2 inhibitor on formulary
- 5. Concurrent antipsychotic continuation not justified
- 6. Quantity limit exceeded
What to Include in a Ingrezza Letter of Medical Necessity
Document confirmed tardive dyskinesia with AIMS score ≥6 (or significant functional impairment), history of exposure to the causative dopamine receptor blocking agent with dates and duration, current psychiatric diagnosis requiring continued antipsychotic therapy if applicable, prior VMAT2 inhibitor trial with outcome if a step-therapy requirement exists, and clinical rationale for once-daily valbenazine (adherence, simplicity, tolerability vs deutetrabenazine).
Key clinical evidence to cite:
- ✓ KINECT 3 Phase 3 trial — significant AIMS score improvement at 6 weeks
- ✓ KINECT 4 — durable response through 48 weeks
- ✓ Once-daily dosing advantage vs deutetrabenazine (twice-daily)
Relevant guidelines:
- 📖 AAN 2013 Tardive Syndromes Guidelines (updated position statements)
- 📖 ASCP 2022 Tardive Dyskinesia Consensus Statement
Ingrezza Prior Authorization Criteria
Standard criteria across major US payers for Ingrezza. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Documented failure or contraindication to formulary alternatives
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Ingrezza
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Ingrezza Prior Authorization FAQ
Why was my Ingrezza prior authorization denied?
The most common denial reasons for Ingrezza are: Tardive dyskinesia diagnosis not documented (requires exposure to dopamine receptor blocking agents); AIMS (Abnormal Involuntary Movement Scale) score not on file; History of dopamine receptor blocking agent exposure not documented (antipsychotic, metoclopramide, etc.); Austedo (deutetrabenazine) as preferred VMAT2 inhibitor on formulary; Concurrent antipsychotic continuation not justified; Quantity limit exceeded.
What should a Ingrezza Letter of Medical Necessity include?
Document confirmed tardive dyskinesia with AIMS score ≥6 (or significant functional impairment), history of exposure to the causative dopamine receptor blocking agent with dates and duration, current psychiatric diagnosis requiring continued antipsychotic therapy if applicable, prior VMAT2 inhibitor trial with outcome if a step-therapy requirement exists, and clinical rationale for once-daily valbenazine (adherence, simplicity, tolerability vs deutetrabenazine).
Which payers cover Ingrezza?
Ingrezza is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Humana, Medicare Part D, though formulary tier and prior authorization criteria vary.